Business Wire

Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types

Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
Business Wire

FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted ...
Morningstar

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines Eligible Manulife customers in Hong Kong ...
Hosted on MSN

Skip the colonoscopy, do a blood test? Why new Shield might be an alternative

Colonoscopy is the gold standard for detecting colon cancer, but every year about 50 million people in the U.S. who qualify for a colonoscopy don't get it done, according to the American Cancer ...